🔬 They aim to modify these cells’ genetics, particularly focusing on energy metabolism issues that lead to cell apoptosis.
💪 The research could significantly benefit rAAV manufacturers by creating viable production methods, advancing the landscape of advanced therapy manufacturing.
Introduction:
The article discusses the innovative research being conducted by scientists from the Novo Nordisk Foundation Center for Biosustainability in Denmark, aimed at addressing the challenges of manufacturing recombinant adeno-associated viruses (rAAVs) using Chinese hamster ovary (CHO) cells, which are the industry standard. The research seeks to identify genetic modifications that could enable these cells to produce rAAVs more effectively.
- Current manufacturing practices using CHO cells fail to produce rAAVs due to inherent cellular limitations.
- The research team has pinpointed disruptions in energy metabolism within CHO cells as a key barrier to rAAV production.
- Researchers plan to modify specific genetic targets related to energy metabolism to enhance the cellular capacity for producing rAAVs.
- Previous attempts by other research groups to produce rAAVs from CHO cells have been largely unsuccessful, and existing methods often involve the use of live viruses, which are not scalable.
- The study aims to develop practical solutions to facilitate the scalability of rAAV manufacturing, providing potential support to the industry by alleviating resource and time constraints.
Conclusion:
This research presents a promising avenue for improving the manufacturing processes of rAAVs, with the potential for significant implications in the field of biomanufacturing. The insights gained regarding cellular energy metabolism may not only lead to the successful production of rAAVs but could also pave the way for enhanced methodologies in advanced therapy manufacturing overall.
